Published in Clin Cancer Res on December 22, 2009
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med (2013) 2.18
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Radiation-induced reprogramming of breast cancer cells. Stem Cells (2012) 1.83
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res (2010) 1.78
Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res (2010) 1.78
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One (2011) 1.67
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res (2012) 1.62
DNA methyltransferases: a novel target for prevention and therapy. Front Oncol (2014) 1.62
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer (2011) 1.62
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res (2011) 1.59
Tissue-based identification of stem cells and epithelial-to-mesenchymal transition in breast cancer. Hum Pathol (2013) 1.50
Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol (2012) 1.50
Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene (2012) 1.49
Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J (2014) 1.30
Circulating tumor cells: from bench to bedside. Annu Rev Med (2012) 1.29
Oncogenic effects of miR-10b in glioblastoma stem cells. J Neurooncol (2013) 1.29
High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget (2015) 1.27
The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal (2010) 1.26
The biology of head and neck cancer stem cells. Oral Oncol (2011) 1.25
Breast cancer stem cells. Int J Biochem Cell Biol (2012) 1.25
Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom (2010) 1.21
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol (2011) 1.16
Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance. Autophagy (2013) 1.15
Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer (2013) 1.14
The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget (2013) 1.13
Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res (2014) 1.11
Aldehyde dehydrogenases: from eye crystallins to metabolic disease and cancer stem cells. Chem Biol Interact (2012) 1.10
A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett (2013) 1.09
The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin Ther Targets (2010) 1.09
CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One (2012) 1.08
Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci (2011) 1.08
Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res (2013) 1.08
In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy. BMC Cancer (2010) 1.07
Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol (2011) 1.07
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (2011) 1.07
Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res (2013) 1.06
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res (2011) 1.06
RhoC impacts the metastatic potential and abundance of breast cancer stem cells. PLoS One (2012) 1.06
Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget (2016) 1.06
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. Pharmacol Ther (2016) 1.06
Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer (2012) 1.03
Phenotypic heterogeneity of breast cancer stem cells. J Oncol (2011) 1.03
The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin Exp Metastasis (2011) 1.03
Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells. Sarcoma (2013) 1.02
ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. PLoS One (2014) 1.01
Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila) (2012) 1.01
Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med (2015) 1.00
Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J Gastroenterol Hepatol (2012) 1.00
New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today (2010) 0.99
Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem (2010) 0.99
Notch Signaling is Associated with ALDH Activity and an Aggressive Metastatic Phenotype in Murine Osteosarcoma Cells. Front Oncol (2013) 0.98
Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis. PLoS One (2013) 0.98
ABC transporters in CSCs membranes as a novel target for treating tumor relapse. Front Pharmacol (2014) 0.98
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Int J Oncol (2012) 0.97
ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC Cancer (2014) 0.97
Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer (2011) 0.97
ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer (2014) 0.97
Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. Breast Cancer Res (2014) 0.97
Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. Stem Cells (2015) 0.96
Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res (2014) 0.96
Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse. Cancer Cell Int (2013) 0.96
Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol (2015) 0.95
Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. Int J Oncol (2012) 0.95
SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma. Oncogene (2015) 0.95
Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer (2010) 0.95
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS One (2014) 0.94
Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PLoS One (2013) 0.93
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle (2013) 0.93
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis (2014) 0.93
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat (2012) 0.93
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist (2012) 0.92
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer (2014) 0.91
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep (2015) 0.91
Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures. BMC Cancer (2012) 0.91
Human osteosarcoma CD49f(-)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity. Oncogene (2012) 0.91
Majority of differentially expressed genes are down-regulated during malignant transformation in a four-stage model. Proc Natl Acad Sci U S A (2013) 0.91
Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer (2012) 0.91
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res Treat (2013) 0.91
NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. J Immunol (2015) 0.91
Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res (2013) 0.90
Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol (2010) 0.90
Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol (Dordr) (2011) 0.90
Cancer stem cell subsets and their relationships. J Transl Med (2011) 0.89
Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential. Clin Sarcoma Res (2011) 0.89
The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil"? Int J Breast Cancer (2011) 0.89
Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck (2014) 0.89
Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med (2012) 0.89
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer (2014) 0.88
Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression. Breast Cancer Res Treat (2013) 0.88
A new method for identifying stem-like cells in esophageal cancer cell lines. J Cancer (2013) 0.88
Cancer: Limitations of therapies exposed. Nature (2012) 0.88
Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer (2013) 0.88
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst (2005) 4.14
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res (2007) 3.63
Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood (2005) 3.51
Therapeutic implications of cancer stem cells. Curr Opin Genet Dev (2004) 3.04
A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res (1999) 2.69
Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer (1999) 2.05
Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol (2009) 1.95
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res (2002) 1.82
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer (2008) 1.76
An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res (2001) 1.65
A novel human xenograft model of inflammatory breast cancer. Cancer Res (1999) 1.61
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res (2004) 1.59
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res (2006) 1.58
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol (2004) 1.53
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res (2004) 1.51
The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol (2008) 1.49
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol (2008) 1.48
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat (2003) 1.36
Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat (2005) 1.29
RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat (2004) 1.25
Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res (2003) 1.24
Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol (2009) 1.19
In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer Cell Int (2005) 1.13
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res (2009) 1.12
Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol (2002) 1.08
Breast cancer stem cell markers - the rocky road to clinical applications. Breast Cancer Res (2008) 1.07
Cancer stem cells are everywhere. Nat Med (2009) 1.03
What progress have we made in managing inflammatory breast cancer? Oncology (Williston Park) (2007) 0.99
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer (2007) 0.87
The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. Future Oncol (2006) 0.85
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
International network of cancer genome projects. Nature (2010) 20.35
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res (2009) 6.43
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol (2006) 4.87
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (2008) 4.84
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
Stem cells in normal breast development and breast cancer. Cell Prolif (2003) 4.47
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol (2009) 4.18
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol (2007) 3.35
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 3.21
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
How basal are triple-negative breast cancers? Int J Cancer (2008) 3.18
Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.18
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Integrated profiling of basal and luminal breast cancers. Cancer Res (2007) 2.86
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol (2010) 2.74
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Colon cancer stem cells: promise of targeted therapy. Gastroenterology (2010) 2.58
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res (2006) 2.52
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 2.50
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res (2005) 2.26
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood (2012) 2.23
Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood (2011) 2.20
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol (2007) 2.20
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol (2011) 2.20